Fig. 2From: Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trialPatient disposition through TP3 (ITT population). aSubjects who completed study treatment and had week-78 joint count assessment. ITT, intent-to-treat; TP3, treatment period 3Back to article page